Pharmacogenetics of Osteoporosis: Future Perspectives

Calcified Tissue International

Volumn 84, Issue 5, 2009, Pages 337-347

  Marini, Francesca ^a   Brandi, Maria Luisa ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

Author keywords

Osteoporosis; Pharmacogenetics; Pharmacogenomics; Regulatory agencies; Translational research

Indexed keywords

ACENOCOUMAROL; ALENDRONIC ACID; BIOLOGICAL MARKER; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; CARRIER PROTEIN; CONJUGATED ESTROGEN PLUS MEDROXYPROGESTERONE ACETATE; CYPROTERONE ACETATE PLUS ESTRADIOL VALERATE; DRUG RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; ESTROGEN; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; ETIDRONIC ACID; IBANDRONIC ACID; PHENPROCOUMON; PROGUANIL; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TRICYCLIC ANTIDEPRESSANT AGENT; VITAMIN D; VITAMIN D RECEPTOR; WARFARIN;

BONE DENSITY; CLINICAL PRACTICE; DRUG EFFICACY; DRUG METABOLISM; DRUG RESPONSE; DRUG SAFETY; GENE INTERACTION; GENETIC MARKER; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOME ANALYSIS; HEART ATRIUM FIBRILLATION; HORMONE SUBSTITUTION; HUMAN; JAW OSTEONECROSIS; LUNG NON SMALL CELL CANCER; OSTEOPOROSIS; PATIENT COMPLIANCE; PHARMACODYNAMICS; PHARMACOGENETICS; PHARMACOGENOMICS; PRIORITY JOURNAL; REVIEW; TREATMENT RESPONSE; VITAMIN SUPPLEMENTATION;

ANIMALS; BIOMEDICAL RESEARCH; BIOTRANSFORMATION; BONE DENSITY CONSERVATION AGENTS; DRUG AND NARCOTIC CONTROL; DRUG EVALUATION, PRECLINICAL; DRUG RESISTANCE; GENETIC VARIATION; HUMANS; OSTEOPOROSIS; PHARMACOGENETICS; SELECTIVE ESTROGEN RECEPTOR MODULATORS;

EID: 67349094884     PISSN: 0171967X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00223-009-9226-x     Document Type: Review

References (45)

1. JC Venter MD Adams EW Myers PW Li RJ Mural GG Sutton HO Smith M Yandell CA Evans RA Holt 2001 The sequence of the human genome Science 291 5507 1304 1351 (Pubitemid 32173090)
2. W Zhang MJ Ratain ME Dolan 2008 The HapMap resource is providing new insights into ourselves and its application to pharmacogenomics Pharmacogenet Genomics 18 6 545 549
3. RS Huang S Duan WK Bleibel EO Kistner W Zhang TA Clark TX Chen AC Schweitzer JE Blume NJ Cox ME Dolan 2007 A genome-wide approach to identify genetic variants that contribute to etoposide-induced cytotoxicity Proc Natl Acad Sci USA 104 23 9758 9763 (Pubitemid 47175340)
4. RS Huang S Duan SJ Shukla EO Kistner TA Clark TX Chen AC Schweitzer JE Blume ME Dolan 2007 Identification of genetic variants contributing to cisplatin-induced cytotoxicity by use of a genomewide approach Am J Hum Genet 81 3 427 437 (Pubitemid 47330203)
5. S Schneeweiss J Hasford M Göttler A Hoffmann AK Riethling J Avorn 2002 Admissions caused by adverse drug events to internal medicine and emergency departments in hospitals: a longitudinal population-based study Eur J Clin Pharmacol 58 4 285 291
6. M Eichelbaum M Ingelman-Sundberg WE Evans 2006 Pharmacogenomics and individualized drug therapy Annu Rev Med 57 119 137 (Pubitemid 43261982)
7. S Marsh DJ Van Booven HL McLeod 2006 Global pharmacogenetics: giving the genome to the masses Pharmacogenomics 7 4 625 631 (Pubitemid 43891418)
8. F Goodsaid F Frueh 2006 Process map proposal for the validation of genomic biomarkers Pharmacogenomics 7 5 773 782 (Pubitemid 44225912)
9. MS Tsao A Sakurada JC Cutz CQ Zhu S Kamel-Reid J Squire I Lorimer T Zhang N Liu M Daneshmand P Marrano G da Cunha Santos A Lagarde F Richardson L Seymour M Whitehead K Ding J Pater FA Shepherd 2005 Erlotinib in lung cancer-molecular and clinical predictors of outcome N Engl J Med 353 2 133 144 (Pubitemid 41058345)
10. DM Jackman BY Yeap LV Sequist N Lindeman AJ Holmes VA Joshi DW Bell MS Huberman B Halmos MS Rabin DA Haber TJ Lynch M Meyerson BE Johnson PA Jänne 2006 Exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in non-small cell lung cancer patients treated with gefitinib or erlotinib Clin Cancer Res 12 13 3908 3914 (Pubitemid 44078074)
11. MK Higashi DL Veenstra LM Kondo AK Wittkowsky SL Srinouanprachanh FM Farin AE Rettie 2002 Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy JAMA 287 13 1690 1698 (Pubitemid 34289221)
12. MJ Rieder AP Reiner BF Gage DA Nickerson CS Eby HL McLeod DK Blough KE Thummel DL Veenstra AE Rettie 2005 Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose N Engl J Med 352 22 2285 2293 (Pubitemid 40740552)
13. GP Aithal CP Day PJ Kesteven AK Daly 1999 Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications Lancet 353 9154 717 719 (Pubitemid 29103806)
14. J Taube D Halsall T Baglin 2000 Influence of cytochrome P-450 CYP2C9 polymorphisms on warfarin sensitivity and risk of over-anticoagulation in patients on long-term treatment Blood 96 5 1816 1819 (Pubitemid 30661066)
15. Roche AmpliChip Package Insert. http://www.amplichip.us/documents/ AmpliChip-CYP450-Test-Package-Insert.pdf
16. www.emea.europa.eu/pdfs/human/pharmacogenetics/2022704en.pdf
17. www.emea.europa.eu/pdfs/human/pharmacogenetics/12851706enfin.pdf
18. TV Nguyen JA Eisman 2006 Pharmacogenomics of osteoporosis: opportunities and challenges J Musculoskelet Neuronal Interact 6 62 72 (Pubitemid 43732829)
19. L Gennari L Becherini A Falchetti L Masi F Massart ML Brandi 2002 Genetics of osteoporosis: role of steroid hormone receptor gene polymorphisms J Steroid Biochem Mol Biol 81 1 1 24
20. YJ Liu H Shen P Xiao DH Xiong LH Li RR Recker HW Deng 2006 Molecular genetic studies of gene identification for osteoporosis: a 2004 update Bone Miner Res 21 10 1511 1535 (Pubitemid 44484596)
21. CJ Rosen CR Kessenich 1997 The pathophysiology and treatment of postmenopausal osteoporosis An evidence-based approach to estrogen replacement therapy. Endocrinol Metab Clin North Am 26 295 311
22. B Ongphiphadhanakul S Chanprasertyothin P Payatikul SS Tung N Piaseu L Chailurkit S Chansirikarn G Puavilai R Rajatanavin 2000 Oestrogen-receptor-alpha gene polymorphism affects response in bone mineral density to oestrogen in post-menopausal women Clin Endocrinol (Oxf) 52 581 585 (Pubitemid 30337083)
23. T Salmén AM Heikkinen A Mahonen H Kröger M Komulainen S Saarikoski R Honkanen PH Mäenpää 2000 The protective effect of hormone-replacement therapy on fracture risk is modulated by estrogen receptor alpha genotype in early postmenopausal women J Bone Miner Res 15 2479 2486
24. T Yahata J Quan N Tamura H Nagata T Kurabayashi K Tanaka 2005 Association between single nucleotide polymorphisms of estrogen receptor alpha gene and efficacy of HRT on bone mineral density in post-menopausal Japanese women Hum Reprod 20 1860 1866 (Pubitemid 40932369)
25. PB Rapuri JC Gallagher JA Knezetic V Haynatzka 2006 Estrogen receptor alpha gene polymorphisms are associated with changes in bone remodeling markers and treatment response to estrogen Maturitas 53 4 371 379 (Pubitemid 43319374)
26. T Kurabayashi M Tomita H Matsushita T Yahata A Honda K Takakuwa K Tanaka 1999 Association of vitamin D and estrogen receptor gene polymorphism with the effect of hormone replacement therapy on bone mineral density in Japanese women Am J Obstet Gynecol 180 1115 1120 (Pubitemid 29259003)
27. T Kurabayashi H Matsushita M Tomita N Kato M Kikuchi H Nagata A Honda T Yahata K Tanaka 2004 Association of vitamin D and estrogen receptor gene polymorphism with the effects of longterm hormone replacement therapy on bone mineral density J Bone Miner Metab 22 241 247 (Pubitemid 38660955)
28. Y Giguère S Dodin C Blanchet K Morgan F Rousseau 2000 The association between heel ultrasound and hormone replacement therapy is modulated by a two-locus vitamin D and estrogen receptor genotype J Bone Miner Res 15 6 1076 1084 (Pubitemid 30350070)
29. Y Liel S Shany P Smirnoff B Schwartz 1999 Estrogen increases 1,25-dihydroxyvitamin D receptors expression and bioresponse in the rat duodenal mucosa Endocrinology 140 1 280 285 (Pubitemid 29011170)
30. M Simsek Z Cetin T Bilgen O Taskin G Luleci I Keser 2008 Effects of hormone replacement therapy on bone mineral density in Turkish patients with or without COL1A1 Sp1 binding site polymorphism J Obstet Gynaecol Res 34 1 73 77
31. EG Lufkin MD Whitaker T Nickelsen R Argueta RH Caplan RK Knickerbocker BL Riggs 1998 Treatment of established postmenopausal osteoporosis with raloxifene: a randomized trial J Bone Miner Res 13 1747 1754 (Pubitemid 28492005)
32. S Palomba FG Numis G Mossetti D Rendina P Vuotto T Russo F Zullo C Nappi V Nunziata 2003 Raloxifene administration in post-menopausal women with osteoporosis: effect of different BsmI vitamin D receptor genotypes Hum Reprod 18 192 198 (Pubitemid 36138876)
33. WC Graafmans P Lips ME Ooms JP van Leeuwen HA Pols AG Uitterlinden 1997 The effect of vitamin D supplementation on the bone mineral density of the femoral neck is associated with vitamin D receptor genotype J Bone Miner Res 12 8 1241 1245 (Pubitemid 27334970)
34. JM Wishart M Horowitz AG Need F Scopacasa HA Morris PM Clifton BE Nordin 1997 Relations between calcium intake, calcitriol, polymorphisms of the vitamin D receptor gene, and calcium absorption in premenopausal women Am J Clin Nutr 65 3 798 802 (Pubitemid 27111088)
35. PD Delmas 2005 The use of bisphosphonates in the treatment of osteoporosis Curr Opin Rheumatol 17 462 466 (Pubitemid 41058407)
36. MC Farrugia DJ Summerlin E Krowiak T Huntley S Freeman R Borrowdale C Tomich 2006 Osteonecrosis of the mandible or maxilla associated with the use of new generation bisphosphonates Laryngoscope 116 115 120 (Pubitemid 44383974)
37. RE Marx Y Sawatari M Fortin V Broumand 2005 Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment J Oral Maxillofac Surg 63 1567 1575 (Pubitemid 41525412)
38. SR Cummings AV Schwartz DM Black 2007 Alendronate and atrial fibrillation N Engl J Med 356 1895 1896 (Pubitemid 46698498)
39. J Marc J Prezelj R Komel A Kocijancic 1999 VDR genotype and response to etidronate therapy in late postmenopausal women Osteoporos Int 10 303 306 (Pubitemid 29476194)
40. S Palomba F Orio Jr T Russo A Falbo A Tolino F Manguso V Nunziata P Mastrantonio G Lombardi F Zullo 2005 BsmI vitamin D receptor genotypes influence the efficacy of antiresorptive treatments in postmenopausal osteoporotic women. A 1-year multicenter, randomized and controlled trial Osteoporos Int 16 943 952 (Pubitemid 41127104)
41. B Arko J Prezelj R Komel A Kocijancic J Marc 2002 No major effect of estrogen receptor beta gene RsaI polymorphism on bone mineral density and response to alendronate therapy in postmenopausal osteoporosis J Steroid Biochem Mol Biol 81 147 152
42. AM Qureshi RJ Herd GM Blake I Fogelman SH Ralston 2002 Colia1 Sp1 polymorphism predicts response of femoral neck bone density to cyclical etidronate therapy Calcif Tissue Int 70 158 163 (Pubitemid 36929595)
43. HL Benford JC Frith S Auriola J Mönkkönen MJ Rogers 1999 Farnesol and geranylgeraniol prevent activation of caspases by aminobisphosphonates: biochemical evidence for two distinct pharmacological classes of bisphosphonate drugs Mol Pharmacol 56 131 140 (Pubitemid 29309821)
44. E van Beek E Pieterman L Cohen C Löwik S Papapoulos 1999 Farnesyl pyrophosphate synthase is the molecular target of nitrogen-containing bisphosphonates Biochem Biophys Res Commun 264 108 111 (Pubitemid 29500472)
45. F Marini A Falchetti S Silvestri Y Bagger E Luzi A Tanini C Christiansen ML Brandi 2008 Modulatory effect of farnesyl pyrophosphate synthase (FDPS) rs2297480 polymorphism on the response to long-term amino-bisphosphonate treatment in postmenopausal osteoporosis Curr Med Res Opin 24 9 2609 2615